Compugen to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Compugen (NASDAQ: CGEN) said management will participate in two investor conferences in late Feb–early Mar 2026: Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) on Feb 26, 2026 and Leerink Partners 2026 Global Healthcare Conference (Miami) on Mar 9, 2026.

Both events include fireside chats and 1x1 meetings; live webcasts and replays will be available on the company's investor relations events page at www.cgen.com.

News Market Reaction – CGEN

+2.06%

4 alerts

+2.06% News Effect

+$3M Valuation Impact

$168M Market Cap

0.9x Rel. Volume

On the day this news was published, CGEN gained 2.06%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $168M at that time.

Data tracked by StockTitan Argus on the day of publication.

HOLON, Israel, Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date: Thursday, February 26, 2026
Location: Virtual
Format: Fireside chat and 1x1 meetings
Fireside chat time: 2 PM ET

Leerink Partners 2026 Global Healthcare Conference
Date: Monday, March 9, 2026
Location: Miami, Florida, U.S.
Format: Fireside chat and 1x1 meetings
Fireside chat time: 8:40 AM ET

Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. Replays will be available following the live events.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen^™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs, consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-upcoming-investor-conferences-302692427.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) present at the Oppenheimer Healthcare Life Sciences Conference?

Compugen will present on Thursday, February 26, 2026 at 2:00 PM ET as a virtual fireside chat. According to Compugen, the session includes a fireside chat and 1x1 meetings, with a live webcast and replay available on the company's investor events page.

What is the date and format of Compugen (CGEN) participation at the Leerink Partners 2026 Global Healthcare Conference?

Compugen will participate Monday, March 9, 2026 with an 8:40 AM ET fireside chat and 1x1 meetings. According to Compugen, the event is in Miami, Florida and the company will provide a live webcast and subsequent replay on its investor website.

How can investors access Compugen (CGEN) fireside chat webcasts and replays?

Investors can watch live webcasts and replays via the events page on Compugen's investor relations website at www.cgen.com. According to Compugen, both the Oppenheimer and Leerink fireside chats will be streamed live and made available for replay afterward.

Which topics will Compugen (CGEN) management likely cover at the investor conferences?

Management will likely discuss corporate strategy, clinical progress, and AI/ML drug discovery priorities during fireside chats. According to Compugen, the company is a clinical-stage cancer immunotherapy developer and a pioneer in computational target discovery, which frames investor discussions.

Will Compugen (CGEN) offer one-on-one meetings with investors at the conferences?

Yes, Compugen indicated management will hold one-on-one meetings in addition to fireside chats at both events. According to Compugen, these 1x1 sessions are intended to facilitate deeper investor discussions and questions following the public presentations.

Where can I find the schedule and replay times for Compugen (CGEN) conference appearances?

The schedule and replay availability are posted on Compugen's investor relations events page at www.cgen.com. According to Compugen, live webcast times are Feb 26, 2026 2:00 PM ET and Mar 9, 2026 8:40 AM ET, with replays afterward.